Lucid Diagnostics Inc (LUCD) PT Raised to $7.75 at Ascendiant Capital

Ascendiant Capital analyst Edward Woo raised the price target on Lucid Diagnostics Inc (NASDAQ: LUCD) to $7.75 (from $7.50) while maintaining a Buy rating.

The analyst comments "Current valuation attractive: We are maintaining our BUY rating, but raising our 12- month price target to $7.75 from $7.50 based on a NPV analysis. This represents significant upside from the current share price and we believe this valuation appropriately balances out the company’s high risks with large upside opportunities."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'